Sign in
Active, not recruitingNo phase

Financial Incentives for Smoking Treatment II

Key facts

Who runs it
University of California, Los Angeles
Where
Los Angeles and New York, United StatesSee the 2 sites
Trial code
Status
Active, not recruiting
People taking part
1,058 people, planned
Started
6 Jan 2020
Expected to end
30 Jun 2027
Type of study
Interventional, 3 groups
Treatments tested
  • Smoking cessation counseling (Quitline)
  • Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)
  • Financial incentives for smoking cessation
  • Financial incentives for use of evidence-based smoking cessation therapies
Record updated
29 April 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • age ≥ 18 years
  • smoked tobacco during the prior 30 days,
  • have an active U.S. phone number and address,
  • can provide consent in English or Spanish and
  • are in at least the contemplative stage of change for quitting smoking, as assessed by a single measure, readiness to quit

Who cannot take part

  • use only smokeless tobacco,
  • are pregnant or breastfeeding,
  • are discharged to an institution (e.g., nursing home, long-term care facility),
  • are unable to provide informed consent, or do not have cognitive ability to enroll or participate in the study

Where in United States

  • David Geffen School of MedicineLos Angeles, United States
  • NYU Langone HealthNew York, United States

About the trial

What the trial wants to find out

Financial incentives for motivating changes in health behavior, particularly for smoking and other morbid habits, are increasingly being tested by health insurers, employers, and government agencies. However, in using incentive programs for smoking cessation, key unanswered structural and theoretical questions remain regarding their effectiveness, acceptability to patients, and economic sustainability. This trial aims to advance the science and implementation of financial incentives for smoking cessation interventions among high-risk, hospitalized smokers. The investigators will pursue two specific aims: 1) comparing the impact of three approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life and 2) comparing the short-term and long term return on investment of using goal directed and outcome-based financial incentives to promote smoking cessation.

The 3 groups in the trial

  • Goal-Directed IncentivesOther group

    Treatment: Smoking cessation counseling (Quitline), Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy), and Financial incentives for use of evidence-based smoking cessation therapies

  • Outcome-Based IncentivesOther group

    Treatment: Smoking cessation counseling (Quitline), Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy), and Financial incentives for smoking cessation

  • Enhanced Usual CareOther group

    Treatment: Smoking cessation counseling (Quitline) and Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Financial Incentives for Smoking Treatment
Publications
Record updated
29 April 2026